Keywords: up, 448m, govt, biothrax, contract, emergent, biosolutions
Up to $448M US govt BioThrax contract
Article | 6 October 2008
Emergent BioSolutions that it has signed a new, multi-year, firm fixed price contract with the US Department of Health and Human Services to supply an additional 14.5 million doses of BioThrax (anthrax vaccine adsorbed), its Food and Drug Administration-licensed anthrax vaccine, for inclusion in the Strategic National Stockpile.
The total value of this follow-on contract is between $364.0 million and $404.0 million, with the higher amount tied to the delivery of product having four-year expiry dating. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
